Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
3.87 | -0.09 (-2.27%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 46,021 |
| Date : | 07-19-2019 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed to Present at World Diabetes Congress
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific [...]
Oramed Announces Xiaoming Gao Joins Board of Directors
Chairman of HTIT has decades of experience in the diabetes sector in China NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral [...]
Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 [...]
Oramed to Present at BIO International Convention
NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business [...]
Investors Tools